Back to UBS Group AG UBS Group AG

TTRXTTRX
2 quarters

Position history for UBS Group AGUBS Group AG's holdings in TURN THERAPEUTICS INC

Yes. Ubs holds 2,263 shares of TTRX (Turn Therapeutics), worth $16,520, as of its Q2 2026 13F filing. It increased the position from 400 shares in Q1 2026. Ubs has held TTRX since Q1 2026, across 2 quarterly 13F filings.

Current Value

$16,520

Current Shares

2,263

Total Value Change

+$15,240

Total Shares Change

+1,863

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
2,263
+465.8%
$16,5200.0%$7.30
20
2026-Q1
New
400
-
$1,2800.0%$3.20
17

Other major holders of TTRX: IEQ CAPITAL, LLC, VANGUARD CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, BlackRock, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used